Oxford Biomedica (OXB)

Sector:

Pharma and Biotech

Index:

FTSE Small Cap

322.00p
   
  • Change Today:
      2.00p
  • 52 Week High: 470.00
  • 52 Week Low: 166.80
  • Currency: UK Pounds
  • Shares Issued: 100.00m
  • Volume: 220,204
  • Market Cap: £322.00m
  • RiskGrade: 125

Oxford BioMedica forms new digital framework initiative

By Josh White

Date: Friday 23 Nov 2018

LONDON (ShareCast) - (Sharecast News) - Gene and cell therapy group Oxford BioMedica announced the formation of a new digital framework initiative on Friday, which it said would streamline the production of next-generation medicines.
The London-listed firm said it would invest a total of £4m, supported by a £2m grant from Innovate UK, in building digital and robotics capabilities that would be designed to drive improvements in analytical methodology, supply times and cost of goods.

It said the goal was to increase capacity, reduce the cost of manufacturing and reduce waste.

The aims of the project were said to be aligned with the UK Government's 'Life Sciences Sector Deal', to help ensure that the next wave of breakthrough treatments, innovative medical research and technologies, and high skill jobs were created in Britain.

Oxford Biomedica said it was committed to investing in the UK, and recently announced the expansion of its manufacturing capacity to create an additional 82,398 square foot facility near its headquarters in Oxford.

That new facility secured Oxford as a bioprocessing centre for the company, the board explained, and would create up to 100 new, highly-skilled positions at the group over the next two years.

"With demand for advanced therapy medicinal products expected to grow at unprecedented levels, underlined by the interest received from our current and future potential partners at Oxford Biomedica, it is imperative that we continue to invest in our technology, capacity and innovation," said chief executive officer John Dawson.

"This new initiative will provide us with digital and robotic enhancements to maintain our global leading position in the development and manufacture of lentiviral vector products.

"This is important for our own research and development pipeline as well as for our blue-chip partners as we continue to support the delivery of life-altering gene therapies to patients around the world."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

OXB Market Data

Currency UK Pounds
Share Price 322.00p
Change Today 2.00p
% Change 0.63 %
52 Week High 470.00
52 Week Low 166.80
Volume 220,204
Shares Issued 100.00m
Market Cap £322.00m
RiskGrade 125

OXB Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
27.13% below the market average27.13% below the market average27.13% below the market average27.13% below the market average27.13% below the market average
21.57% above the sector average21.57% above the sector average21.57% above the sector average21.57% above the sector average21.57% above the sector average
Price Trend
3.01% below the market average3.01% below the market average3.01% below the market average3.01% below the market average3.01% below the market average
48.15% above the sector average48.15% above the sector average48.15% above the sector average48.15% above the sector average48.15% above the sector average
Income Not Available
Growth
52.21% below the market average52.21% below the market average52.21% below the market average52.21% below the market average52.21% below the market average
58.82% below the sector average58.82% below the sector average58.82% below the sector average58.82% below the sector average58.82% below the sector average

What The Brokers Say

Strong Buy 1
Buy 3
Neutral 6
Sell 0
Strong Sell 0
Total 10
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

OXB Dividends

No dividends found

Trades for 15-May-2024

Time Volume / Share Price
16:35 25,047 @ 322.00p
16:35 87 @ 322.00p
16:35 36 @ 322.00p
16:35 36 @ 322.00p
16:35 22 @ 322.00p

OXB Key Personnel

CFO Stuart Paynter
CEO Frank Mathias

Top of Page